A newly developed low dose T1W-DCE-MRI method, ACcomb, was used to estimate the absolute CBF of vestibular schwannomas (VS) and normal appearing brain tissue in a group of 12 consecutive type 2 neurofibromatosis (NF2) patients, undergoing anti-angiogenic bevacizumab treatment. This new method consistently displayed excellent gray-white matter flow contrast and produced mean GM and WM CBF estimates consistent with previous literature values. Use of this new method showed that at 90 days post bevacizumab treatment, there was increased positive correlation between CBF and estimated plasma volume within the VS, and a significant increase in CBF within normal appearing white matter.
This abstract and the presentation materials are available to members only; a login is required.